Experimental Peri-implant Mucositis on Implant Sites That Were Previously Treated With or Without Implantoplasty

Experimental Peri-implant Mucositis on Implant Sites That Were Previously Treated With or Without Implantoplasty

Progression and Resolution of Experimental Peri-implant Mucositis on Now Healthy Implant Sites That Were Previously Treated With or Without Implantoplasty: A Controlled Clinical Trial

This controlled clinical trial will assess clinically, immunologically, and microbiologically the healing of experimental peri-implant mucositis (PIM) lesions in implants treated previously with implantoplasty (IP) compared to those treated without IP.

The present parallel controlled clinical trial is designed as a 21-day experimental peri-implant mucositis, followed by a period of resolution of 21 days in healthy implants that were previously treated for peri-implantitis with and without implantoplasty. A total of 8 appointments over the course of about 42 days will be necessary. These appointments will take place in the Department of Periodontics & Preventive Dentistry and are described as follows: Screening Appointment (14 days prior to Day 0): During this visit, informed consent will be obtained from each subject and inclusion criteria for participation in the study will be reviewed. Participants will undergo the following activities: Review of medical, dental history and medications Periodontal chart Intraoral photographs Periapical radiograph of the dental implant that was previously treated with or without implantoplasty to confirm if the implant is in healthy condition with no progressive bone loss A digital impression (intraoral scan) of the teeth will be taken for fabrication of a customized stent (a plastic cover). The participant will be instructed to place the stent over the implant whenever performing oral care measures (brushing/flossing/mouthrinse) at home for 21 days. The authors will teach the individuals on how to use this stent and how to brush the teeth/implant(s) during the study. The stent will be provided at the next research visit. A professional prophylaxis (dental cleaning) of all tooth and implant surfaces. V2 - V5 (from day 0 to day 21), the experimentally induced peri-implant mucositis phase, the participant will be wearing the stent over the implant area during their routine oral health care. The following research activities will occur: Review any changes to medical or dental history and any new medications Intraoral photographs Clinical assessment Peri-implant crevicular fluid sample collection from the deepest pocket around the implant using paper points. Biofilm sample collection using sterile curettes (titanium or plastic) at the same sites. At V5 (day 21), the participants will receive a dental cleaning, polishing, and review of their oral hygiene home care techniques. Then, they will be asked to reinstitute their oral hygiene home care procedures. At V6 - V8 (from day 28 to day 42), the resolution of induced peri-implant mucositis phase, the following research activities will occur: Review any changes to medical or dental history and any new medications Intraoral photographs Clinical assessment Peri-implant crevicular fluid sample collection from the deepest pocket around the implant using paper points. Biofilm sample collection using sterile curettes (titanium or plastic) at the same sites. At V8 (day 42), a new periapical radiograph will be acquired. If there is still any evidence of inflammation around the implant, we will continue to monitor/treat the inflammation every 3-4 weeks until it is resolved. PERI-IMPLANT CREVICULAR FLUID (PICF) SAMPLING AND ANALYSIS: PICF samples will be collected weekly. The site with the deepest pocket of each implant will be sampled using sterile Periopapers with colored bands (29 mm, ISO 25, taper .02; VDW, Munich, Germany). At each visit following screening (V2-V8), the samples will be taken from the same site. The PICF volume will be measured with a calibrated, electronic gingival fluid measuring device (Periotron 8000, Oraflow, Plainview, NY, USA). Cytokines will be detected using a panel of relevant cytokines using a bead based multiplex immunoassay (Bio-Plex Pro Human Cytokine 27-plex Assay). SUBMUCOSAL PLAQUE SAMPLING AND DNA EXTRACTION Sterile curettes (titanium or plastic) will be used to collect plaque samples from the deepest pocket around each implant. DNA will be extracted using DNeasy Blood and Tissue Kit (Qiagen). Genomic DNA samples will be profiled with 16S Amplicon Sequencing Service. Microbial composition will be profiled with Centrifuge using bacterial, viral, fungal, and human genome datasets.

Implant(s) treated previously for peri-implantitis with or without exposed polished surface, no PD > 4 mm and < 50% bone loss.

Patients will refrain from oral hygiene measures at the implant sites for 3 weeks to induce peri-implant mucositis, by using a stent in the included implant during oral hygiene.

Patients will reinstitute oral hygiene measures, receive an oral prophylaxis and oral hygiene instructions and will be evaluated during 3 weeks.

The mGI will be assessed according to the following criteria: Score 0 - No bleeding on probing; Score 1 - Bleeding dot; Score 2 - Continuous line of blood that fills the sulcus; Score 3 - Profuse bleeding and/or hemorrhage drip. Changes in the scores between day 21 and day 42 will be determined, being 0 minimum and 3 maximum. The mGI will be assessed weekly.

The mPI will be assessed according to the following criteria: Score 0 - No visible plaque; Score 1 - Plaque only recognized by running a probe across the marginal surface; Score 2 - Plaque can be seen by the naked eye; Score 3 - Abundance of soft matter The mPI will be assessed weekly, being 0 minimum and 3 maximum.

PD will be accessed weekly. Increase in PD must exceed a threshold of 0.8mm to be considered progression of the disease.

Measured by overlaying the baseline and final radiographs and measuring the change in marginal bone levels. Progression will have to exceed a threshold of 0.5mm to be considered.

PICF will be collected from the same sites weekly with the aid of paper strips. Cytokines will be detected using a panel of relevant cytokines using a bead based multiplex immunoassay to determine the immunological profile of the lesions during induction and resolution of peri-implant mucositis.

Plaque samples will be collected weekly and qualitative/quantitatively evaluated by 16S rRNA sequencing for composition profiling during the induction and resolution of peri-implant mucositis.

Inclusion Criteria: Aged 18-80 years In good general health, (at least ASA 2) Previously treated implants must have probing depths (PD) ≤ 4 mm Previously treated implants must have <50% bone loss around the implant of interest (assessed radiographically) Patients must have been treated previously for peri-implantitis with or without IP, with at least 1 thread or 2 mm of implant surface exposed in the oral cavity. Have little to no bacteria on the implant(s) of interest (modified Plaque Index of <1) by Day 0 Have healthy gums that do not bleed around the implant(s) of choice (modified Gingival index <1) by Day 0 Have evidence of stable bone levels around the treated implant for > 6 months Exclusion Criteria: Active infectious diseases of any kind. Medical conditions which require premedication prior to dental treatments/visits. Pregnant women or planning to become pregnant (self-reported). Patients with congenital or metabolic bone disorders (ie. osteoporosis, vitamin D deficiency, parathyroid disease, etc.) Current heavy smokers: Subjects who have smoked more than 1 pack/day within 6 months of study onset (self-reported) Subjects with co-morbid conditions (i.e., uncontrolled diabetes, cardiovascular disease, impaired kidney function, heart murmur, rheumatic fever, bleeding disorder, hepatitis, tuberculosis, HIV) that would affect the study outcome or interpretation of study results will be excluded. Concomitant medications: Subjects on significant concomitant drug therapy for systemic conditions (i.e., Chronic anti-inflammatory medication, antibiotics, anticoagulants, any medication initiated <3 months prior to the screening visit) will not be included in the study. Occasional short-term use (7-14 days) of analgesics or common cold medication is permitted. Such use of these medications will be reviewed and recorded by the Investigator.